MicroRNA‑15a‑5p induces pulmonary artery smooth muscle cell apoptosis in a pulmonary arterial hypertension model via the VEGF/p38/MMP‑2 signaling pathway

Zhang,Wenmei; Li,Yanna; Xi,Xin; Zhu,Guangfa; Wang,Shenghao; Liu,Yan; Song,Man

doi:10.3892/ijmm.2019.4434

MicroRNA‑15a‑5p induces pulmonary artery smooth muscle cell apoptosis in a pulmonary arterial hypertension model via the VEGF/p38/MMP‑2 signaling pathway

Authors:
- Wenmei Zhang
- Yanna Li
- Xin Xi
- Guangfa Zhu
- Shenghao Wang
- Yan Liu
- Man Song
View Affiliations

Affiliations: Department of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, P.R. China, Department of Obstetrics and Gynecology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, P.R. China, Infectious Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, P.R. China
Published online on: December 18, 2019 https://doi.org/10.3892/ijmm.2019.4434
Pages: 461-474
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the role of microRNA‑15a‑5p (miR‑15a‑5p) in pulmonary arterial hypertension (PAH) and elucidate the underlying pro‑apoptotic mechanism. Reverse transcription‑quantitative PCR analysis and gene microarray hybridization were used to measure the expression of miR‑15a‑5p in the lung tissues of rats with monocrotaline (MCT)‑induced PAH. Flow cytometry and caspase‑3/9 activity assays were adopted to measure the apoptosis of pulmonary artery smooth muscle cells (PASMCs). The expression of apoptosis‑related proteins was analyzed using western blotting. The results demonstrated that the expression of miR‑15a‑5p was significantly increased in the lung tissues of rats with MCT‑induced PAH. In addition, the overexpression of miR‑15a‑5p reduced PASMC proliferation, induced apoptosis, promoted the activity of caspase‑3/9, induced the protein expression of B‑cell lymphoma 2‑associated X protein (Bax), decreased the expression of B‑cell lymphoma 2 (Bcl‑2), increased inflammation, as indicated by the expression of tumor necrosis factor‑α (TNF)‑α and interleukin (IL)‑1β, IL‑6 and IL‑18, suppressed the protein expression of vascular endothelial growth factor (VEGF), and promoted the protein expression levels of phosphorylated (p)‑p38 mitogen‑activated protein kinase (p38) and matrix metalloproteinase (MMP)‑2 in the PASMCs of rats with MCT‑induced PAH. By contrast, the downregulation of miR‑15a‑5p increased cell proliferation, decreased apoptosis, reduced the activity of caspase‑3/9 and the protein expression of Bax, increased the expression of Bcl‑2, inhibited inflammation (as suggested by the expression of TNF‑α, IL‑1β, IL‑6 and IL‑18), induced the protein expression of VEGF, and suppressed the protein expression of p‑p38 and MMP‑2 in the PASMCs of rats with MCT‑induced PAH. The inhibition of VEGF attenuated the effects of the overexpression of miR‑15a‑5p on the inhibition of cell proliferation, apoptotic rate, caspase‑3/9 activity and protein expression of Bax, and it attenuated the increased inflammation, as indicated by the protein expression of p38 and MMP‑2 in the PASMCs. In conclusion, the data of the present study demonstrated that miR‑15a‑5p induced the apoptosis of PASMCs in an animal model of PAH via the VEGF/p38/MMP‑2 signaling pathway. However, further research is required to fully elucidate the role of miR‑15a‑5p in the development of PAH.

View Figures

View References

1	Veeraraghavan S, Koss MN and Sharma OP: Pulmonary veno-occlusive disease. Curr Opin Pulm Med. 5:310–313. 1999. View Article : Google Scholar : PubMed/NCBI
2	Prins KW and Thenappan T: World health organization group I pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin. 34:363–74. 2016. View Article : Google Scholar : PubMed/NCBI
3	Dorfmuller P, Perros F, Balabanian K and Humbert M: Inflammation in pulmonary arterial hypertension. Eur Respir J. 22:358–363. 2003. View Article : Google Scholar : PubMed/NCBI
4	Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF and Rabinovitch M: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 43(12 Suppl S): pp. 13S–24S. 2004, View Article : Google Scholar
5	Akagi S, Nakamura K, Akagi T, Nakagawa K, Takaya Y, Sarashina T, Ejiri K and Ito H: Feasibility of repairing defects followed by treatment with pulmonary hypertension-specific drugs (Repair and Treat) in patients with pulmonary hypertension associated with atrial septal defect: Study protocol for interventional trial. Acta Med Okayama. 70:397–400. 2016.PubMed/NCBI
6	Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
7	Portt L, Norman G, Clapp C, Greenwood M and Greenwood MT: Anti-apoptosis and cell survival: A review. Biochim Biophys Acta. 1813:238–359. 2011. View Article : Google Scholar
8	Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay E, Lambert C, Jacob MH, Bonnet SN, et al: Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J. 40:618–629. 2012. View Article : Google Scholar : PubMed/NCBI
9	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
10	Fischer SEJ: RNA interference and MicroRNA-mediated silencing. Curr Protoc Mol Biol. 112:26.1.1–26.1.5. 2015. View Article : Google Scholar
11	Naveed A, Ur-Rahman S, Abdullah S and Naveed MA: A concise review of MicroRNA exploring the insights of MicroRNA regulations in bacterial, viral and metabolic diseases. Mol Biotechnol. 59:518–529. 2017. View Article : Google Scholar : PubMed/NCBI
12	Yun EJ, Lorizio W, Seedorf G, Abman SH and Vu TH: VEGF and endothelium-derived retinoic acid regulate lung vascular and alveolar development. Am J Physiol Lung Cell Mol Physiol. 310:L287–L298. 2016. View Article : Google Scholar :
13	Muratore CS, Nguyen HT, Ziegler MM and Wilson JM: Stretch-induced upregulation of VEGF gene expression in murine pulmonary culture: A role for angiogenesis in lung development. J Pediatr Surg. 35:906–912. 2000. View Article : Google Scholar : PubMed/NCBI
14	Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, Raffestin B and Frelin C: Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol. 275:H1948–H1956. 1998.PubMed/NCBI
15	Tuder RM, Flook BE and Voelkel NF: Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest. 95:1798–1807. 1995. View Article : Google Scholar : PubMed/NCBI
16	Chen H and Tian Y: MiR-15a-5p regulates viability and matrix degradation of human osteoarthritis chondrocytes via targeting VEGFA. Biosci Trends. 10:482–488. 2017. View Article : Google Scholar
17	Shang J, He Q, Chen Y, Yu D, Sun L, Cheng G, Liu D, Xiao J and Zhao Z: miR-15a-5p suppresses inflammation and fibrosis of peritoneal mesothelial cells induced by peritoneal dialysis via targeting VEGFA. J Cell Physiol. 234:9746–9755. 2019. View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-timequantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Woik N and Kroll J: Regulation of lung development and regeneration by the vascular system. Cell Mol Life Sci. 72:2709–2718. 2015. View Article : Google Scholar : PubMed/NCBI
20	Voelkel NF and Gomez-Arroyo J: The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am J Respir Cell Mol Biol. 51:474–484. 2014. View Article : Google Scholar : PubMed/NCBI
21	Sergi C: EPAS 1, congenital heart disease, and high altitude: Disclosures by genetics, bioinformatics, and experimental embryology. Biosci Rep. 39:pii: BSR20182197. 2019. View Article : Google Scholar : PubMed/NCBI
22	Papaioannou AI, Zakynthinos E, Kostikas K, Kiropoulos T, Koutsokera A, Ziogas A, Koutroumpas A, Sakkas L, Gourgoulianis KI and Daniil ZD: Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm Med. 9:182009. View Article : Google Scholar : PubMed/NCBI
23	Saleby J, Bouzina H, Lundgren J and Radegran G: Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension. Scand Cardiovasc J. 51:261–270. 2017. View Article : Google Scholar : PubMed/NCBI
24	Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J and Voelkel NF: Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 106:1311–1319. 2000. View Article : Google Scholar : PubMed/NCBI
25	Chaudhary KR, Deng Y, Suen CM, Taha M, Petersen TH, Mei SHJ and Stewart DJ: Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: Haemodynamic benefits are not associated with improvements in arterial remodelling. Br J Pharmacol. 175:3976–3989. 2018. View Article : Google Scholar : PubMed/NCBI
26	Ye EA, Liu L and Steinle JJ: miR-15a/16 inhibits TGF-beta3/VEGF signaling and increases retinal endothelial cell barrier proteins. Vision Res. 139:23–29. 2017. View Article : Google Scholar : PubMed/NCBI
27	Schermuly RT, Ghofrani HA, Wilkins MR and Grimminger F: Mechanisms of disease: Pulmonary arterial hypertension. Nat Rev Cardiol. 8:443–455. 2011. View Article : Google Scholar : PubMed/NCBI
28	Rabinovitch M, Guignabert C, Humbert M and Nicolls MR: Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 115:165–175. 2014. View Article : Google Scholar : PubMed/NCBI
29	Liu Y, Liu LY, Jia Y, Sun YY and Ma FZ: Role of microRNA-15a-5p in the atherosclerotic inflammatory response and arterial injury improvement of diabetic by targeting FASN. Biosci Rep. 39:pii: BSR2018. 18522019. View Article : Google Scholar
30	Jia X, Hu X, Han S, Miao X, Liu H, Li X, Lin Z, Wang Z and Gong W: Increased M1 macrophages in young miR-15a/16^−/− mice with tumour grafts or dextran sulphate sodium-induced colitis. Scand J Immunol. 8:e127032018. View Article : Google Scholar
31	Davidovich P, Kearney CJ and Martin SJ: Inflammatory outcomes of apoptosis, necrosis and necroptosis. Biol Chem. 395:1163–1171. 2014. View Article : Google Scholar : PubMed/NCBI
32	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
33	Ferrari G, Terushkin V, Wolff MJ, Zhang X, Valacca C, Poggio P, Pintucci G and Mignatti P: TGF-β1 induces endothelial cell apoptosis by shifting VEGF activation of p38(MAPK) from the prosurvival p38β to proapoptotic p38α. Mol Cancer Res. 10:605–614. 2012. View Article : Google Scholar : PubMed/NCBI
34	Shi C, Huang F, Gu X, Zhang M, Wen J, Wang X, You L, Cui X, Ji C and Guo X: Adipogenic miRNA and meta-signature miRNAs involved in human adipocyte differentiation and obesity. Oncotarget. 7:40830–40845. 2016.PubMed/NCBI
35	Thenappan T, Chan SY and Weir EK: Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 315:H1322–H1331. 2018. View Article : Google Scholar : PubMed/NCBI
36	Bihlet AR, Karsdal MA, Sand JM, Leeming DJ, Roberts M, White W and Bowler R: Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD. Respir Res. 18:222017. View Article : Google Scholar : PubMed/NCBI
37	Jablonska-Trypuc A, Matejczyk M and Rosochacki S: Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 31(Sup 1): S177–S183. 2016. View Article : Google Scholar
38	Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, Cubel G, Taras D, Blanc JF, Robinson DR and Rosenbaum J: Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol. 169:1390–1401. 2006. View Article : Google Scholar : PubMed/NCBI
39	Mukherjee A, Adhikari N and Jha T: A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line. Eur J Med Chem. 141:37–50. 2017. View Article : Google Scholar : PubMed/NCBI
40	Yu H, Zhong Q, Xia Y, Li E, Wang S and Ren R: MicroRNA-2861 targets STAT3 and MMP2 to regulate the proliferation and apoptosis of ectopic endometrial cells in endometriosis. Pharmazie. 74:243–249. 2019.PubMed/NCBI
41	Hassan M, Watari H, AbuAlmaaty A, Ohba Y and Sakuragi N: Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
42	Chen D, Wu D, Shao K, Ye B, Huang J and Gao Y: MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia. Am J Transl Res. 9:4308–4316. 2017.PubMed/NCBI